ActRIIB, active
10 µg of active ActRIIB. N-Terminal GST-tagged, recombinant, human ActRIIB amino acids 185-488.
Biological information
Background
ActRIIB (Activin receptor type-2B) is a type II transmembrane serine/threonine kinase receptor that is involved in the signaling of members of the TGF-β superfamily of cytokines, including activin, myostatin, and growth and differentiation factor 11 (GDF11). ActRIIB signaling has been shown to inhibit muscle growth and promote muscle wasting through the activation of the Smad2/3 signaling pathway and the subsequent repression of muscle-specific genes. Research has suggested that targeting ActRIIB signaling may be a potential therapeutic strategy for the treatment of muscle wasting diseases, such as sarcopenia, cachexia, and muscular dystrophy. Several drugs targeting ActRIIB signaling, including the myostatin inhibitors and selective androgen receptor modulators (SARMs), are currently in clinical development as potential therapies for these conditions.
Target class
Kinase
Family
TKL
Accession number
NM_001106.3
Target Name
ActRIIB, active
Target Alias
ACVR2B; Activin A Receptor Type 2B; Activin Receptor Type-2B; HTX4
Origin
Human
Theori. MW
61 kDa
Affinity tag
GST
Product specifications
Expression system
Expressed by baculovirus in Sf21 insect cells
Purity
Purity 90% by SDS-PAGE and Coomassie blue staining
Purification method
glutathione agarose
Sample Buffer
enzyme in 50 mM Tris/HCl pH 7.5, 300 mM NaCl, 0.1 mM EGTA, 0.03% Brij-35, 270 mM sucrose, 1 mM benzamidine, 0.2 mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution
Specified activity
Refer to CoA
Application
For Research Only
Storage conditions
1 year at -70°C.
Usage disclaimer
For Research Only
Chemical data
Background
ActRIIB (Activin receptor type-2B) is a type II transmembrane serine/threonine kinase receptor that is involved in the signaling of members of the TGF-β superfamily of cytokines, including activin, myostatin, and growth and differentiation factor 11 (GDF11). ActRIIB signaling has been shown to inhibit muscle growth and promote muscle wasting through the activation of the Smad2/3 signaling pathway and the subsequent repression of muscle-specific genes. Research has suggested that targeting ActRIIB signaling may be a potential therapeutic strategy for the treatment of muscle wasting diseases, such as sarcopenia, cachexia, and muscular dystrophy. Several drugs targeting ActRIIB signaling, including the myostatin inhibitors and selective androgen receptor modulators (SARMs), are currently in clinical development as potential therapies for these conditions.
Compound name
Kinase
Catalog number
16-052
Molecular formula
CAS
MW
Ka
Percent composition
Product specifications
Physical state
Purity (HPLC 214nm)
Retention time (RP18 HPLC)
CMC
Exact mass
Stability
For Research Only
Solubility structure
Datasheets
16-052
Datasheet